BWX Technologies, Inc.

Ladies and gentlemen, welcome to VWX Technologies' second quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. Following the company's prepared remarks, we will conduct a question and answer session and instructions will be given at that time. I would now like to turn the call over to our host, Chase Jacobson, VWXT's Vice President of Investor Relations. Please go ahead, sir.

Thank you.

Good evening and welcome to today's call. Joining me are Rex Jeviden, President and CEO, and Mike Fitzgerald, Senior Vice President and CFO. On today's call, we will reference the second quarter 2025 earnings presentation that is available on the Investor section of the VWX website. We will also discuss certain matters that constitute forward-looking statements. These statements involve risks and uncertainties, including those described in the Safe Harbor provision found in the investor materials in the company's SEC filing. We will frequently discuss non-GAAP financial measures, which are reconciled to GAAP measures in the appendix of the earnings presentation that can be found on the Investor section of the VWX website. I would now like to turn the call over to Rex.

Thank you, Chase, and good evening to all of you. First, I would like to welcome Mike Fitzgerald, our CFO, to the call. Mike has been with VWXG since 2022 and previously held the roles of Chief Accounting Officer, Head of Finance, and CFO of Government Operations. He is deeply ingrained in our business, is a trusted resource for the entire executive team, and I'm happy to have him on the call with us today. Now turning to our results and a discussion of our markets and outlook. Second quarter financial results exceeded our expectations, driven by strong execution and pacing of work in government operations. Our second quarter financial results featured double-digit adjusted EBITDA and earnings for share growth and robust free cash flow. We closed the acquisition of Kinetrix in May. Kinetrix brings a workforce of over 1,300 employees and significantly broadens our life plant services capabilities in the nuclear power and energy infrastructure markets, enabling us to offer an even broader range of services to the market. Demand across the global security, clean energy, and medical end markets is accelerating. Backlog grew to 6 billion, up 23% quarter over quarter, and 70% year over year with growth in both segments. Organic book to bill was 2.2 in the quarter, and the pipeline with new opportunities and government and commercial operations is expanding. Turning to segment results and market outlook, government operations revenue was up 9% and adjusted EBITDA up 23%, exceeding our expectations. Results were driven by strong execution, particularly within the special materials portfolio, the AOT acquisition, and timing of material procurement. The naval propulsion business is focused on driving operational excellence and maintaining production pace on our franchise submarine and aircraft carrier programs. As we announced last month, we signed the next pricing agreement for naval nuclear reactor components. The agreement is valued at 2.6 billion over the next eight years, primarily related to Virginia and Columbia class submarines and certain components for Ford class aircraft carriers. We booked over 1 billion in orders on this contract in the second quarter, driving government operations backlog to 4.4 billion, up 24% sequentially and up 55% compared to the second quarter of last year. This contract follows a 2.1 billion dollar pricing agreement we signed in late 2024, which combined with the administration's focus on naval shipbuilding and the submarine industrial base, supports our longer term forecast of a 3 to 5% revenue cager in this line of business. Special materials remains one of the most exciting growth stories at our company. We had strong performance on legacy contracts during the quarter and our growth prospects are brightening. The experiential qualifications and unique licenses we possess are well matched with national security missions and position us to satisfy strategic priorities for our customers. We have nearly completed the one year engineering study for defense uranium enrichment using the DEUCE technology to satisfy naval fuel and national security needs under contract to the NNSA. Our current focus is responding to the sole source RFP issued in April for the next phase of this program, which includes design, licensing and construction of pilot plants. Additionally, we are working with the NNSA on long term production of high purity depleted uranium in quantities that exceed our business case expectations for the AOT acquisition. We are also tracking several advanced nuclear fuel opportunities intended for defense and commercial applications. We will keep you posted as these prospects take shape. In microreactors, we began manufacturing the reactor core for PELAY, the land-based transportable microreactor. PELAY has received strong support in recent government funding bills and is highly aligned with the president's national security executive order titled Deploying Advanced Nuclear Reactor Technologies that directs the DOD to commence operations of a nuclear reactor by September 2028. As PELAY progresses and the advanced fuel supply chain grows, there are multiple emerging opportunities that BWXT is well positioned to capture. In technical services, results are strong inside operational performance and in contract wins. Operating income from this business line was up over 20% compared to the average quarterly rate over the last year and we are on track to outpace that growth for the full year. This is driven by the ramp at Pantex and Hanford, both of which began in 2024, and newer projects such as West Valley and the Strategic Petroleum Reserve, the latter of which is expected to commence in the second half of the year. From a new business perspective, Atomic Energy Canada Limited selected Nuclear Laboratory Partners of Canada, a BWXT-led joint venture which also includes Kinectrix, to manage and operate Canadian Nuclear Laboratories, our first international project in this line of business. The annual contract value is about $1.2 billion Canadian dollars with an initial term of six years and extensions for up to 20 years. We are in the preferred bidder period and expect a transition to a contract start date late in the third quarter. Turning to commercial operations, reported revenue growth was 24%. On an organic basis, revenue was down 3% and largely in line with our expectation as double digit growth in medical was offset by a modest decline in commercial power due to the timing of outage and maintenance projects as we discussed last quarter. Backlog in the segment grew to $1.6 billion, including about $240 million from the Kinectrix acquisition. On an organic basis, booked to bill in the quarter was $1.3. Importantly, this was driven by a multitude of contracts for existing nuclear power infrastructure, highlighting the strong underlying base of revenue in our portfolio and supporting our full year outlook for mid-teens organic growth and over 50% growth including contribution from Kinectrix. BWXT medical delivered a solid quarter with double digit revenue growth driven by the TEP diagnostic product lines and TheraSphere. Robust demand signals for the diagnostic and therapeutic isotopes support the outlook for over 20% growth this year. In product development, the Canadian Nuclear Safety Commission approved the irradiation of Yeatrium-90 and Leuticium-177 using the target delivery system with Lorenz's energy partners at the Darlington site. On TEC-99, as we discussed last quarter, we've been perfecting the product attributes. Encouragingly, we have line of sight to address the final technical issues that are typical in the scale-up and industrialization phase of complex projects and I am quite encouraged by our progress. Given the timing, I don't expect a product launch this year, but customer appetite remains strong and this will be an important addition to our fast-growing portfolio of medical isotopes. Turning now to commercial power, where demand is accelerating rapidly, in the can-do market we have talked in depth about the opportunities in the ongoing life extensions and the potential for large-scale new builds. Ontario Power Generation and Bruce Power are evaluating options to expand their nuclear reactor fleets to meet increasing electricity demand in the region. While these projects are in the planning stages, BWXT and Kinetrix are trusted partners in the Canadian nuclear market and are engaging with these utilities now. For the AP1000, we are betting on component engineering and manufacturing contracts across a global opportunity set. There continues to be good momentum in the SMR market. In July, the NRC accepted TVA's construction permit application to build a GE Hitachi BWRX300 at Clinch River in Tennessee, with the review expected to be complete by the end of next year. This would be a giant step in the US SMR market and would complement the progress in Canada at the Darlington site for which BWXT is manufacturing the reactor pressure vessel and other important components potentially. In addition to our work with GE Hitachi, we are also working with TerraPower, Rolls-Royce, and others as we anticipate multiple follow-on orders in the coming years. Our long history of manufacturing large complex nuclear components and existential and expanding capacity position us as a super merchant supplier to the SMR market. With that, I will now turn the call over to Mike.

Thank you, Rex, and good evening, everyone. Very happy to be here. I've had a chance to meet with a number of you recently and I look forward to meeting with more of you in the coming months. I'll start with some total company financial highlights on slide four of the earnings presentation. Second quarter revenue was $764 million, up 12%, with growth in both segments. Excluding contributions from acquisitions, organic revenue was up 4%. Adjusted EBITDA was $146 million, up 16% year over year, driven by robust double-digit growth in government operations, which was partially offset by lower adjusted EBITDA in commercial operations. Corporate expense was lower compared to last year, and we continue to expect corporate adjusted EBITDA expense in 2025 to be slightly lower than the $16.8 million reported last year. Adjusted earnings per share were $1.02, up 24%, driven by strong operating performance, complemented by a lower tax rate, foreign currency gains, and higher pension income, which were partially offset by higher interest expense due to debt associated with the Kinetrix and AOT acquisitions. Our adjusted effective tax rate was 20% for the quarter, which was lower than anticipated due to various tax credits, as well as higher stock compensation expense. Given the lower second quarter tax rate, we now expect our full year tax rate to be approximately 21%. This yields a second half tax rate of approximately 22.5%, which is more in line with our expectation of our tax rate going forward. Free cash flow in the quarter was a robust $126 million, driven by good working capital management. Capital expenditures in the quarter were $33 million, or .3% of sales, due to timing of growth investments being more back half-weighted during the year. We now expect capital expenditures to be .5% to 6% of sales for the year, driven by investments to meet growing end market demand, including the ongoing expansion of our Cambridge Commercial Nuclear Manufacturing Facility and infrastructure investments related to defense fuels and government operations. Moving now to segment results on slide six. In government operations, second quarter revenue was up 9%, driven by growth in naval propulsion, timing of material procurements, special materials performance, and just over 2% contribution from the AOT acquisition. Adjusted EBITDA was up 23% year over year to $133 million, yielding an adjusted EBITDA margin of 22.6%. This was driven by favorable mix, strong operating performance, and favorable contract performance in our special materials portfolio. We continue to expect government operations to generate -single-digit revenue growth in 2025. However, with stronger margin performance in the first half, we now anticipate adjusted EBITDA margin to be approximately .5% for the year. Turning to commercial operations, revenue was $176 million, up 24% year over year, driven by contribution from the Kinetrix acquisition in double-digit growth in medical, which was partially offset by a modest decline in commercial power, as Rex discussed. Excluding Kinetrix, organic revenue was down 3%. Specific to commercial power, while we had strong revenue growth and components work on the VWRX300 reactor pressure vessel and Pickering steam generators, this was more than offset by the expected decline in field services due to timing of key outage and maintenance projects during the year. Adjusted EBITDA in the segment was $16 million, compared to $23 million last year. This resulted in an adjusted EBITDA margin of 9.2%. While we had solid margin performance in commercial power, components, and fuel, this was offset by the decline in field services and growth investment to match the robust market demand. To provide some additional perspective, within commercial power, field services, one of our higher margin business lines was just over 10% of revenue in the quarter, down from over 35% in the same period last year. This unfavorable mix accounted for over half of the -over-year margin decline, with the remainder due to unfavorable absorption of higher SG&A given lower revenue in the quarter. At this segment level, we now expect commercial operations revenue to grow over 50%, with mid-teens organic growth complemented by the Kinetrix acquisition. However, adjusted EBITDA margin is expected to be .5% to 14%, compared to the low end of 14% to 15% previously, due to growth investment and modestly higher contribution from Kinetrix. Still, our guidance implies significantly improved results in the second half of the year, with higher revenue, more favorable mix, and the absence of commodity price pressure that acutely impacted our first quarter results. Turning now to our 2025 total company guidance on slides seven and eight of the earnings presentation. We are raising our guidance for revenue, adjusted EBITDA, and earnings per share, and increasing the low end of our free cash flow guidance. We now anticipate revenue of approximately $3.1 billion, with modestly better revenue assumptions across the business, as well as contributions from a slightly earlier close of the Kinetrix acquisition. Accordingly, we're raising our adjusted EBITDA guidance to $565 to $575 million, up $10 million at the midpoint, as the stronger operational performance in government and slightly higher revenue in commercial is partially offset by mix and growth investment, as I previously discussed. These changes to our operating outlook, combined with a lower tax rate and better pension and other income, yield an increase in our adjusted EPS guidance, the $3.65 to $3.75 per share. This is up about $0.23 at the midpoint, compared to our original guidance, with half of the operating items I previously discussed. Lastly, we are increasing our free cash flow guidance to $275 to $285 million, up $10 million at the low end, as higher income and benefits from tax legislation are partially offset by slightly higher capex. Overall, we had a strong second quarter and are well positioned to meet our increased guidance for the year. With that, I will turn it back to Rex for closing remarks.

Rex Chisholm Thanks, Mike. Over the past decade as a standalone public company, BWXT has invested both organically and inorganically to enhance our capabilities in the nuclear market. We have built significant industrial scale, and our customers are increasingly relying on BWXT to meet their needs. We have had a strong start to the year, both financially and strategically. Our backlog is at a record level. Demand across our end markets is accelerating, and our intense focus on operational excellence positions us well to continue to drive shareholder value in the years ahead. And with that, we look forward to taking your questions.

Q&A Thank you. We will now begin the question and answer session. If you have dialed in and would like to ask a question, please press star 1 on your telephone keypad to raise your hand and join the queue. If you would like to withdraw a question, simply press star 1 again. If you are called upon to ask your question and are listening via speakerphone on your device, please pick up your handset to ensure that your phone is not on mute when asking your question. We do request for today's session that you please limit to one question and one follow-up question. Again, press star 1

to join the queue. Q&A And our first

question comes from the line of Scott Deuschel with Deuschabank. Your line is open.

Hey, good evening. Mike, the 10Q flags a $29 million favorable contract adjustment, I think, on nuclear operations. Can you clarify any more what that relates to and if any of that was assumed in the original guide?

Q&A Yeah, thanks, Scott. The $29 million, as you mentioned in the 10Q, relates to one of the special materials contracts. Rex mentioned we had strong operating performance in special materials. Scott, as you know, we look at a number of different potential opportunities as it looks to those contracts. So the portion of that was included in the guide, but I would say it was a little bit more favorable than we had originally anticipated. So I would say a part of it we assumed in our original guidance.

Q&A Okay, great. And then, Rex, do you see any opportunity for B2XT to secure some level of content on new build AP1000s that may be built at some point in the US? And if so, what type of content would the company be able to compete for on those reactors?

Yeah, I

do,

Scott. We have, in fact, we have an MOU with Wessinghouse to potentially manufacture certain components for the AP1000 in the US market and potentially in other markets. And what we would do there is what we, similar to what we do and can do, we're qualified for pressure components, high pressure components like steam generators, heat exchangers. We could make that reactor pressure vessel in our Cambridge plant. So there's a lot there. And I think as industrial capacity starts to stretch, we might have some really interesting opportunities there.

Okay, and just to clarify, could your content on that potentially be as large as can do, or would it be still materially smaller?

Yeah, I'm not sure if I'd go that far. We'll have to see how that unfolds. For can do, of course, we typically get all the steam generators, most of the heat exchangers, feeders, and other such content. I'd say it's the same kind of scope of equipment, but I don't know if we would sort of run the table like we do at can do.

Okay, thank you. Thank you.

Our

next question comes from the line of Jeff Campbell with Seaport. Your line is open.

Good afternoon and congratulations on the strong quarter. I thought I'd start with one kind of high-level question, then I got a specific for the second. I thought the appointment of Kevin McCoy, the Chief Nuclear Officer, was clearly important, but it's not clear to me how you will influence bottlenecks that don't historically reside at BWXT. So any high-level commentary you can provide there is certainly appreciated.

Yeah, Jeff, I didn't quite catch the question. Would you be good enough to repeat it? Sure.

I

was saying that I noted Kevin McCoy's appointment to Chief Nuclear Officer with interest, but I wasn't really sure what his mandate will be since BWXT is usually not the point of dragging when we have difficulties getting these projects through. So just any commentary that you can provide on how he's going to influence the... Oh, I got you. Yeah, thank you. Right, okay. I understand the question now. Right, so you're quite correct in the way that title is normally used. And let me just say that that's a bit of a sort of a holding place for Kevin. And the reason for that is that Kevin is seconded to the Department of Defense to help the Deputy Secretary of Defense and the Secretary of the Navy with nuclear shipbuilding. So he remains an executive employee of BWXT, but he's fully under contract to the Navy. And so that's the title that he's holding while he's occupying those positions with the Navy. In the meantime, we promoted Joe Bellerop into President of Government Operations to replace Kevin. So it's all part of that dynamic. Okay, yeah, that makes a lot more sense. My other question was slide seven, the government operations margins of approximately 20.5%. That seems well above prior guidance. I just wondered if you could pinpoint some drivers of this improvement and maybe their durability. Thanks. I don't know.

Yeah, so geomargin for the quarter was impacted by the EAC for the special materials contract that we just mentioned. We also had some really good pacing of work, as well as some of the timing of materials that was good from an overall margin standpoint. I mean, overall, I would say, you know, we're comfortable and we're happy with, you know, some of the efficiencies and utilizations that we're seeing at the plants. We think, you know, we're continuing to focus on that from a margin standpoint to create some long-term sustainability there. We'll see continued strong performance for the rest of the year and we'll give more clarity around what we're expecting in 26 next quarter.

Okay, great. Thank you.

Okay. Next

question comes from the line of Robert Labick with CJS Securities. Your line is open.

Good afternoon. Thanks for taking my questions and congrats to Mike on his new role.

Thank you.

Sure. I wanted to start, Rex, you mentioned this in your prepared remarks, but yeah, you had the recent approval by the CNSC to irradiate yttrium and lutetium in your target delivery system. Can you talk about the opportunity there? What are the next steps and, you know, what it'll take for you to, you know, get that through, done, and produce commercial material?

Sure, Bob. Yeah, we're doing that in partnership with Laurentius Energy Partners, as I said in the script, and the qualification of those products is really up to our partner. They're the ones that develop the contracts to produce that material for certain clients. And so we have a bit of a passive role there. We did design and deploy that target delivery system. And so it'll be

a, it'll be a royalty opportunity for us.

Okay, great. And then just switching gears a little bit for my follow up. You have, you know, a tremendous amount of opportunities ahead of you. You talked about the DOOS, growth, pay lay, build out, etc. Talk about capital allocation. How do you prioritize, you know, capital into each of these? What are the big amounts of capital that you need to deploy over the next five to 10 years for any of these or other opportunities and how you allocate?

Yeah, maybe I'll start and then flip it over to Mike. You know, we've given broad guidance that, you know, 4% for maintenance capex surging up to perhaps 5% or 6% episodically, depending on the opportunity. We're doing the Cambridge plant build out right now, which is obviously not maintenance capex. And that's sort of 1% of our sales right now. And so that that pushes it up at that 4% to 6% range. And I think that's how we see it. We don't, we don't see in the windshield by any capex super cycles like we've been through, at least at the present moment. So I think you'd see it banded in that range, 4 to 6, as to how we evaluate it. It's obviously, it's obviously business case. And we've got so many high quality business cases right now and so much competition for capital, it's actually pretty tough. But, you know, that goes with the abundance of opportunities that we're facing. Maybe I'll pitch it over to Mike for any additional comments. Yeah,

right. That's right. The only other thing I'd call out is, you know, we did raise guidance and expectations for capex to 5.5 to 6%. Part of that is driven by some investments we're making around defense fuels related to enrichment. But but as Rex mentioned, you know, we see this and I think we've we've said before, we anticipate, you know, more of 10s of millions of dollars in investments in some of these opportunities. But we don't see that at the same level of significant capex than we may have seen in the past.

Super. All right. Thanks very much.

Our next question comes from the line of David Strauss with Barclays. Your line is open.

Hi, good afternoon. This is Josh Coran on for David. So you've gotten two Navy contracts now in quick succession. How far out are you contracted for for those Navy programs?

Those contracts have a performance period

of up to eight years. It's typical for the delivery of a full ship set to take between six and eight years, depending on whether that's Virginia, Columbia or Ford. So eight years from time we signed the contract.

OK, thanks. And then want to ask, so with Kinetrix closing a little earlier than than you expected, how much did that contribute to the guidance increase? And then in the free cash flow guidance, what are you assuming for working capital? Thanks.

Yeah, so, you know, we

had previously said Kinetrix about mid year, you know, as we mentioned, we look at a number of different scenarios. So you're right, it was it was a few weeks ahead of you know, what we had planned. So part of what you're seeing in the guidance raise relates to I would say that that's a smaller portion. If you think about kind of the Kinetrix at an EPS level, it is, you know, slightly neutralized by the additional interest expense associated with funding from the acquisition. And so when you look at it from that standpoint, it's a small amount. I think most of the raise really, really relates to kind of, you know, timing and pacing of work, as well as our performance in our government operations business. And then as it relates to kind of working capital, you know, from a from an overall working capital standpoint, and I don't know if this was specific to Kinetrix, but we are anticipating, you know, kind of working capital and free cash flow generation similar to the rest of our business. So over 80% free cash flow generation specific

to Kinetrix.

Okay, thanks. Next question comes from

the line of Pete Skabitzky with Alembic. Your line is open.

Hey, good evening, guys. Nice quarter. Hey, Rex. Hey, Rex, if I could follow up, I think it was Josh's question on the two naval reactor contracts in the last call it six or seven months or so. I feel like historically, the Navy is kind of on a you know, like an annual pace with you guys. But now we've got kind of a quicker pace with the Navy. So I think that's a good especially this latest one, a pretty sizable award. Can you give us a sense of what's kind of motivating the Navy? Because I don't know if this is, you know, industrial based funding or wage growth or but I don't really think of you guys as being kind of a bottleneck on submarine construction, right? So I'm just wondering if you can give us a sense of kind of what the motivation is here to for these size of awards and this kind of compressed timeframe?

Yeah, hey, that was so the way that worked out this last pricing agreement that we announced, the $2.6 billion one was really kind of on time. You may remember on the last one that we had a number of delays and that related to the complexity of that negotiation. And it was complex because we had gone through COVID had a lot of labor and commodity price pressure. And it took a while to get through that. And so this one kind of came on time, the prior one came pretty late. So the pace is still the same. We're still receiving orders to the 30 year shipbuilding plan that the Navy has. But I would say what's significant about it is, you know, there are concerns about whether or not, you know, the shipyards will keep pace with the supply chain. And we've, you know, we have offered that we believe that the Navy's approach is going to be to try to, you know, to fix the problem of the shipyards and keep the supply chain running at base. And so this last pricing agreement kind of validates that thesis. You know, it has, you know, two Virginias per year, Columbia is now serial ordering, and then the next board when it comes. And so I think it was kind of important from that perspective to say that, at least for us, the supply chain stayed on schedule.

Okay, got it. Got it. So yeah, so don't expect the next one till 2026, it seems like is what we should think.

That's

that's

it depends, you know, sometimes it's on two year intervals, sometimes on three. So, so we'll see how that unfolds with our customer.

Okay, okay. And just one follow up with me that in your prepared remarks that your comments about several advanced nuclear fuel opportunities. I feel like in the past, you guys have said that you're not really interested in commercial fuel opportunities. I just wanted to validate if that's still true that these fuel opportunities are they are they largely the government at this point?

So not exactly. I'd say there's, you know, an interesting, smallish, but an interesting demand signal for triso fuel that we're responding to, and we can produce that fuel commercially. We're literally the only the only company that can produce triso at any scale. So there's commercial interest, and I expect we'll get a couple of contracts in that area this year. And then I think the other the other comment was around the other indication was around on the front of the fuel cycle for the defense enrichment program that we're involved with, you know, depending on the scale of that thing and on how it unfolds, or it could be commercial outlets for for that material. So I'd say a couple of opportunities there that are interesting

to us. Okay, great. Thank you.

You're welcome. Our next question comes from the line of

Andre Madrid with BTIG. Your line is open.

Good afternoon, guys. Thanks for taking my question. Hey, Andre. Looking at microreactor, I know a lot of moving pieces there. Looks like paylays progressing well. You know, I guess how should we think about that end market in the near medium term, given the progress on Pele, the loss of Draco? Is there any contribution from Jetson still just trying to figure out what the moving pieces are?

Yeah, I'd say Andre, the so let me let me take those by part. For Pele, yeah, it's progressing. We're assembling the reactor core now as we as we have discussed. I was in the Pentagon just within the last month talking to Pat the head is for for government microreactors. And it looks like the government strategy is going to be a competitive offering to put microreactors at multiple DOD sites. So this is what we had always hoped. We had hoped that Pele would become a maybe a low rate initial production program with production programs to follow. And I think that could happen. Now that's in the you know, that's certainly in the future a couple of years, but I think that's the end point for it. Concerning Draco. So Draco hasn't gone away. Just to be clear about that, DARPA withdrew its participation from kind of a joint venture with NASA to develop that nuclear thermal propulsion technology. But the NASA program is is is going ahead. In fact, the the CGS appropriation marks for Pele, sorry, for Draco for nuclear thermal propulsion were 175 million on the House side and 110 million on the Senate side. So it looks like we will have a program going forward through NASA to develop that technology. And I'm actually pretty optimistic about that one. In terms of Jetson, the other program that you talked about, there's a sliver of a program there. It's a smallish thing. And then we have some other pieces, fission surface power and other such programs. And I think I think from what I'm hearing, NASA's really gear up on fission surface power pretty quickly. So there's a lot there. And I think we'll

have a significant role in some of it.

Okay, that's that's definitely promising. Good to hear. And then I guess, moving in a different direction, I guess just talking about naval nuclear supply chain more broadly, I think one of your peers talked about the prospect of taking more work off the plates of the shipyards in order to help clear up some of those bottlenecks. Is that something that you guys would ever be interested in doing? Or is it kind of been there done that don't really want to do that anymore? I know this is something that I think you guys have explored before, but I wasn't sure if you're maybe taking a look at it with fresh eyes.

I'd say generally, it's not of high interest to us if it's not, you know, nuclear qualified components. And that work would not be for the most part. So I wouldn't put it at the top of my list.

Got it. Got it. Okay, no, that makes sense. And one more if I could squeeze it in. I guess, you know, looking at the supply chain again, to stick on that any further impacts related to zirconium? What are you guys seeing there? Does it look like it's getting better, getting worse?

Seems to have leveled out and certainly went through a spike there. And Mike talked about it in his remarks, it impacted us in the first quarter. There was a modest, unbearing minus impact in the second quarter. But just as a reminder, that zirconium price variability is the reason why we don't accept that risk in our contract. So that passes through to the customer. The impact was merely a timing impact related to how we do the percentage complete contract. So that comes, that bounces back to us. So I think it's first

and settled down. Second, comes back to us in the end.

Got it. Got it. I appreciate the clarification, Max. I'll leave it there. Thanks so much.

Thank you.

Our next question comes from the line of Jed Dorsheimer with William Blair. Your line is open.

Hey, guys, you have Mark Shooter on for Jed. Given all the new enthusiasm

and the government support, can you try to place a metric on the engagement level you're seeing now versus a quarter ago or a year ago? Maybe on a number of projects you're bidding on actively

or an increase of revenue opportunity?

Well, hard to answer that

one, Mark. I would say we certainly see high activity in every one of our end markets. Medical's been compounding the 20% per year. The government appetite seems to be stronger than ever. In fact, I've said earlier today that we can't outgrow the government business. Commercial power, the opportunities are abundant. Yeah, the markets are just strong everywhere and we

certainly haven't experienced a time like this. I appreciate it. I thought I'd ask. Just switching gears a

bit to the Triso fuel. I think I heard you mention that you expect some contracts by the end of the year. Can you wrap that in any kind of unit economics or maybe a capacity? Can you give us any more color on what we should be expecting there and is that going to be any significant impact to the financials this or maybe even next year?

Yeah,

I'd say I don't want to be specific about timing and say I would be a little bit cautious about the scale of those. They're smallish. They're certainly smaller than the pay lay contract, fuel contracts, but I think they're interesting because we're beginning to see the precipitation of modest demand for Triso fuel on the commercial side. So it's exciting strategically. It's not

big economically yet. Great. Thank you,

guys. Next question comes from the line

of Johns, France, Engelbrecht with Beard. Your line is open.

Good evening, Rex, Mike and Chase. The first question I just want to start on the reconciliation bill. There's a lot of big dollars across shipbuilding, the support for the nuclear triad. So I just wanted to get your thoughts, how you're thinking about that and any sort of incremental orders that you expect can start to flow to BWXT where it wouldn't have existed if there was no reconciliation bill.

Yeah, reconciliation bill was good for us. There was funding in there for a second, Virginia for 2026, of course. There was, if I recall it correctly, $100 million for defense enrichment, which obviously is right in our wheelhouse and what we're working on with the National Nuclear Security Administration. There was funding that was specific to advanced reactors. You can read that as pay lay. There was additional funding for the Strategic Capabilities Office. And so when you stack all that up, I think it was all quite edifying to programs that we had in the progress.

Great, thanks, Rex. And just a quick follow-up on the BWRX300. Just on that first reactor in Darlington, how should we think about the revenue recognition? Sort of when does that peak for the first reactor? And I guess to add to that question, is there the potential for the TVA deployment to sort of leapfrog reactors two to four at Darlington? So just as we think about those two sort of locations and just the revenue cadence for reactor one

on the TVA design.

What we said historically on the revenue profile for that X300 is that, well, first we said the opportunity per X300 is in range of $100 million, and then the revenue profile was kind of evenly distributed over, let's call it, a four-year period. And the reason for that is the reactor pressure vessel. And certain other components that we could manufacture tend to be long-leaning items for those reactors. In fact, we received the order for the project that's formally approved by the provincial government. And so you can think about it that way. In terms of the timing for TVA, I don't know if it will leapfrog two, three, and four at Darlington. I mean, I hope so. I hope it goes fast. But I think both of those opportunities, if you think about that opportunity, it's probably four more X300s added to the additional three at Darlington. And so it remains an exciting opportunity for us. I would think what would happen is, maybe the first reactor at TVA falls somewhere in the middle of all

that. But I'm speculating. Okay, Chris. Thank you. It's pretty helpful. I'll jump back in with you. Congrats on a strong quarter.

Thank you. Thank you.

And our next question comes from the line of Mike Charmoli with Shuri Securities. Your line is open.

Hey, good evening, guys. Nice result for the super merchant supplier, Rex. On the guidance here, I know timing is always hard to predict. But the guidance assumes GEO revenues could actually be down second half year over year. And I guess, you've been looking at the EBITDA margin run rate. I know you got the positive EAC. But that second half run rate looks like it might be below 20%. You haven't done that in quite some time. Was it all just timing? Is there anything going on with the mix of some of these newer programs? Should we just think about more cost plus coming in? Or what's the best you can help us with on that week or second half?

Yeah, I would say I don't think we're seeing a major shift in overall mix across the contract portfolios. But what I would say is, we signed the pricing agreement that we mentioned a little bit ahead of schedule. That had a number of advanced material procurements that came into the quarter that we weren't expecting that typically would be in the back half of the year. I would say in addition to that, when you look at the special materials contract performance, typically the fourth quarter is a very strong quarter for us. And in a lot of cases, we're seeing strong performance at that point in the year. We've seen and we're able to get very confident in our contract performance in Q2, which is where you're seeing some outsize growth in the quarter. So when we look at the rest of the year, I think the way that we look at it, we feel confident. And where we'll land, I don't think there's anything individually to call out too much around overall revenue. But I would just say that we're seeing a number of things hit earlier in the year than we typically do.

Okay. Maybe I'll just add a footnote to that. We're just going to add a footnote to what Mike just said, Mike. You know, the operating condition of the plans is good. We've had a focused campaign around op-ats with multiple dimensions to it, including factory throughput, lead time, cost of poor quality, price of non-conformance is the name of our program. So the plants in Cambridge and across Canada, the plants in our NOG complex are performing quite well. I think we just had a very strong performance in the first half and it'll normalize a little bit in the second half, but we feel good about our operational performance. So there's no degradation from that perspective.

Okay. Okay. And then just kind of on that topic, maybe the inverse here, commercial, it sounds like you've got good line of sight to that field services. I thought that was a good color, Mike, providing the kind of percent of revenue, but presumably you get a pickup in field services and that drives the margin strength in commercial second half.

That's right. Yeah. So

we were down,

you

know, seasonally compared to normally Q2 is a strong, you know, quarter for us, but obviously we saw a significant decline, you know, down to 10% revenue in that mix. So we feel good about where the rest of the year will shake out. And I think we're confident in what we're going to see in field services and the components margins for the next two quarters.

Okay. Perfect. Thank you guys. I'll be back in a Q.

And

our last question comes from the line of Ron Epstein with BAML. Your line is open.

Hello. Good afternoon, guys. Yeah, maybe just a couple of quick ones. One, when you look at growth in the backlog, it bumped up a lot.

How much of that is because of the acquisition and how much of that is organic? Yeah. So from the majority of

that is going to be organic. If you look at, you know, ultimately our book, the bill for this quarter was 2.2. We had really about 240 million-ish of backlog associated with the acquisitions, but the majority of it was organic.

Got it. All right. Great. Great. That's super. And then one more. We've heard some companies talking this quarter about, you know, shortages of critical minerals. Has that been an issue for you guys? Do you see it as a potential issue and how are you mitigating it or is it just not an issue at all?

Yeah, maybe I'll take that one. Ron, we're not seeing much pressure from that. The zirconium pricing that you saw in the first quarter was a derivative of that problem, but that seems to be settling out now, as I said earlier. Apart from that, we manage our commodity risk pretty well and aren't that sensitive to critical minerals. Yeah, it's just not moving the needle for us.

Yeah, the only thing I would say, I mean, we're not having an issue trying to get in the actual raw materials. And then from a pricing perspective, we typically, and I think we've publicly said in the past that we, you know, our arrangements will have kind of pricing locked in for, you know, roughly 70% over all materials purchases on our contracts. And that's either due to firm vendor quotes, extended ordering periods, those types of things. And so that's how we're able to manage.

Got it. All right, cool. All right. Thank you.

That concludes the question and answer session. I would like to turn the call back over to Mr. Chase Jacobson for closing remarks.

Thank you. Thanks, everybody, for joining today. We look forward to seeing many of you and speaking with you in the upcoming weeks at investor events or on the phone. And if you have any questions, please feel free to reach out to me at investors at BWXT.com. Thank you.

Ladies and gentlemen, that concludes today's call. Thank you all for joining and you may now disconnect.

Please wait. The conference will begin shortly.